Clinical trial NCT02989012: Phase IIaTrials of GanMaoKangNing Granules
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Epidemic Influenza
Lead sponsor: Dalian Zhen-Ao Bio-Tech Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2016-12-12
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized, double-blind, double- simulation, positive drug-and-Placebo-Controlled, multicenter, phase IIa clinical trials Study about GanMaoKangNing Granules in improving the symptoms of influenza.


Eligibility criteria: Inclusion Criteria:

* Sign the informed consent;
* Male and female patients aged between 18 and 65 years old , there is no limit on the gender;
* In line with the diagnostic criteria for pandemic influenza;
* Duration less than 48 (Duration is defined as the time from onset to test drugs for the first time before, the onset time pointed out that now the axillary temperature 38.0 ℃, headache, muscle or joint pain, chills, fatigue, cough, sore throat and a stuffy nose eight any flu symptoms and signs in time);
* The axillary temperature is 38.0 ℃ or higher;
* Nose and throat swabs rapid virus antigen test result is positive.

Exclusion Criteria:

* Severe influenza and of patients with complications of influenza.
* With the following any severe risk factors:

A. With chronic respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease (copd), etc.

B. with chronic diseases of the cardiovascular system, such as congestive heart failure, high blood pressure.

C. with chronic metabolic and endocrine system diseases, such as poorly controlled diabetes (HbA1c 7.0% or higher).

D. with chronic kidney disease, chronic liver disease, blood system diseases, neurological and neuromuscular diseases (such as epilepsy, cognitive impairment, etc.).

E. A weakened immune system, such as long-term use of immunosuppressive agents, HIV infection or tumor.

F. Under the age of 19, long-term aspirin use. G. The obese (BMI BMI \> 30).

* With influenza complications, such as secondary bacterial pneumonia and other pathogenic bacteria and other viral pneumonia caused by pneumonia.
* A history of peptic ulcer disease or gastrointestinal bleeding.
* Into the group received within 48 h before flu antiviral treatment.
* Into the group of 12 months before been vaccinated against the flu.
* Into the group used within 2 weeks before the monoamine oxidase inhibitors.
* Blood leukocyte count \> 10.0 x 109 / L, neutrophils ratio \> 80%, or the need for systemic antibiotic therapy.
* For GanMaoKangNing Granules, Oseltamivir Phosphate Capsules, Acetaminophen Tablets, Dextromethorphan Hydrobromide Capsule, GanMaoKangNing Granules simulation agent or Oseltamivir Phosphate Capsules simulation agent composition of allergy, or allergic constitution.
* Aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≥ 1.5 x Upper Limit Normal (ULN)， Scr \> Upper Limit Normal (ULN).
* Doubt or does have a history of alcohol or drug abuse.
* Pregnancy (defined as the pregnancy test positive), nursing mothers, or past in family planning.
* For nearly three months participated in other clinical trials of patients.
* Researchers think not appropriate to participate in this clinical subjects.

Primary outcomes:
measure: Flu recovery time
timeFrame: six days
Secondary outcomes:
measure: Single symptom remission rate
timeFrame: six days
measure: The antifebrile effect
timeFrame: six days
Other outcomes:
measure: The conditions of drug utilization of the antipyretic and some cough medicine
timeFrame: six days
Locations:
city: Beijing Shi
country: China
facility: Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
state: Beijing
Study officials:
References: